Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 4,667 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients

NCT00643734
View directory record Official record
Conditions
Pneumonia
Interventions
azithromycin sustained release, placebo, levofloxacin
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
35
States / cities
Mesa, Arizona • Phoenix, Arizona • San Luis Obispo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Not applicable Interventional

Innovative Approach to Reduce Lung Cancer Stigma

NCT03750864
View directory record Official record
Conditions
Lung Cancer Stigma, Lung Cancer, Stigma, Social, Stigmatization, Acceptance Processes
Interventions
ACT-LCS Therapy
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 31, 2026, 2:29 AM EDT
Terminated Phase 1Phase 2 Interventional

DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

NCT00298298
View directory record Official record
Conditions
Non-Small Cell Lung Cancer - Completely Resectable
Interventions
L-Vax: Autologous, DNP-Modified NSCLC Vaccine
Biological
Lead sponsor
AVAX Technologies
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Fayetteville, Arkansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Oral Prednisolone Dosing in Children Hospitalized With Asthma

NCT00257933
View directory record Official record
Conditions
Asthma
Interventions
Prednisolone high dose, Prednisolone lower dose
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 31, 2010 · Synced Oct 31, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

NCT00787644
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Etirinotecan pegol (NKTR-102)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 31, 2026, 2:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Acute Respiratory Infection Consortium

NCT01021098
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
17 Years to 55 Years
Enrollment
2,018 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 31, 2026, 2:29 AM EDT
Terminated Not applicable Interventional Results available

Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD

NCT03901534
View directory record Official record
Conditions
Interstitial Lung Disease, Obstructive Sleep Apnea
Interventions
Continuous positive airway pressure (CPAP) therapy, Nox A1 Recorder
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 31, 2026, 2:29 AM EDT
Terminated No phase listed Observational

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

NCT02121899
View directory record Official record
Conditions
Lung Cancer, NSCLC, NSCLC Adenocarcinoma
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

NCT00305487
View directory record Official record
Conditions
Hay Fever, Seasonal Allergic Rhinitis
Interventions
Ciclesonide nasal spray
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
71
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT00086463
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
Interventions
Iloprost or placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2011 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

NCT01495663
View directory record Official record
Conditions
Cancer
Interventions
I-131-CLR1404
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

NCT00375193
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Amrubicin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
44
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Ocala, Florida + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

New Jersey Healthcare Essential Worker Outreach and Education Study - Testing Overlooked Occupations

NCT04766333
View directory record Official record
Conditions
Covid19, Health Care Seeking Behavior, Health Behavior
Interventions
Healthcare Worker Focused Outreach, Community Organization Led Outreach
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
4 Years and older
Enrollment
2,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 31, 2026, 2:29 AM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 31, 2026, 2:29 AM EDT
Not yet recruiting Phase 3 Interventional

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

NCT01394679
View directory record Official record
Conditions
Lung Cancer
Interventions
(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose), 18 F FDG followed by PET/CT imaging
Drug
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

NCT01202279
View directory record Official record
Conditions
Acute Upper Respiratory Track Infection
Interventions
Guaifenesin, Placebo
Drug · Device
Lead sponsor
Reckitt Benckiser Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Mesa, Arizona • Carmichael, California • Fresno, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 31, 2026, 2:29 AM EDT
Active, not recruiting Phase 2 Interventional

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

NCT05690503
View directory record Official record
Conditions
Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction
Interventions
CI-581a, CI-581b
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 31, 2026, 2:29 AM EDT
Suspended Phase 2 Interventional

Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial

NCT07123961
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Ventilator Management, Lung-protective Ventilation, Pediatric Acute Respiratory Distress Syndrome (PARDS)
Interventions
High Driving Pressure Mechanical Ventilation, Low Driving Pressure Mechanical Ventilation
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Weeks to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 2:29 AM EDT
Completed No phase listed Observational

HRV as a Marker of Treatment Response in PAH Arterial Hypertension

NCT04451850
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Noninvasive actigraphy monitor
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Not applicable Interventional Results available

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil

NCT01317550
View directory record Official record
Conditions
Lung Cancer
Interventions
Armodafinil, Placebo, Minocycline, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 31, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

NCT01431950
View directory record Official record
Conditions
Asthma
Interventions
fluticasone furoate, albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 100 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Long Beach, California • Newport Beach, California • Colorado Springs, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 31, 2026, 2:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

NCT01843374
View directory record Official record
Conditions
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions
Tremelimumab, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

NCT00041574
View directory record Official record
Conditions
Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 31, 2026, 2:29 AM EDT